| Sep 14 |
GSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trial
|
| Sep 14 |
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
|
| Aug 28 |
iTeos to Participate in Upcoming Investor Conferences
|
| Aug 25 |
We're Keeping An Eye On iTeos Therapeutics' (NASDAQ:ITOS) Cash Burn Rate
|
| Aug 20 |
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
|
| Aug 8 |
iTeos Therapeutics GAAP EPS of -$0.18
|
| Aug 8 |
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 8 |
iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates
|
| Aug 5 |
iTeos Therapeutics appoints David Feltquate as chief medical officer
|
| Aug 5 |
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
|
